Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine
| Autor: | Lane B. Donaldson, Yuan F. Liu, Habib G. Rizk, D Macias, James R. Dornhoffer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Botulinum Toxins Migraine Disorders Botulinum toxin injection Nortriptyline Dizziness Injections Young Adult 03 medical and health sciences 0302 clinical medicine Oscillopsia Pharmacotherapy Refractory Risk Factors Topiramate Internal medicine medicine Humans Treatment Failure Stage (cooking) 030223 otorhinolaryngology Aged Retrospective Studies Aged 80 and over Vestibular system business.industry Retrospective cohort study General Medicine Middle Aged Propranolol Botulinum toxin Verapamil Otorhinolaryngology Female medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | The Journal of Laryngology & Otology. 134:586-591 |
| ISSN: | 1748-5460 0022-2151 |
| DOI: | 10.1017/s002221512000095x |
| Popis: | ObjectiveGiven the lack of evidence on patients with medically refractory vestibular migraine, this study aimed to identify factors associated with pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine.MethodsA retrospective cohort study was conducted on definite vestibular migraine patients from September 2015 to July 2019 who completed the Dizziness Handicap Inventory at least six weeks apart..ResultsThe study comprised 47 patients (mean age = 50.2 ± 15.8 years), with a mean follow-up time of 6.0 ± 6.0 months. The mean pre-treatment Dizziness Handicap Inventory score was 57.5 ± 23.5, with a mean reduction of 17.3 ± 25.2 (p < 0.001) at last follow up. Oscillopsia (r = 0.458, p = 0.007), failure of first medication (r = 0.518, p = 0.001) and pre-treatment Dizziness Handicap Inventory question 15 (an emotional domain question) score (r = 0.364, p = 0.019) were the only variables significantly correlated with progression to botulinum toxin injection.ConclusionMotion hypersensitivity, failure of first medication, and fear of social stigmatisation suggest a decreased treatment response. These symptoms may require more aggressive treatment at an earlier stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|